Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants

• DOI: 10.1016/j.vaccine.2024.126164
• Publication Date: 2024-07-30T03:30:33Z
• Authors: Gebremedhin B. Ge...; Man Wah Yeung; Raphael Ximenes; Alexandra Cernat; Alison E. Simmons; April Killikelly; Winnie Siu; Ellen Rafferty; Nicholas Brousseau; Matthew Tunis; Ashleigh R. Tuite
• Keywords: Mononegavirales; Disease Prevention

Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease.